Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and

Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares
      Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex
                           Biotechnology Index Fund

PR Newswire

CHICAGO, June 12, 2013

CHICAGO, June 12, 2013 /PRNewswire/ -- Today, Zacks Investment Ideas feature
highlights Features: Market Vectors Biotech ETF (AMEX:BBH-Free Report),
iShares Nasdaq Biotechnology ETF (Nasdaq:IBB-Free Report), Regeneron
(Nasdaq:REGN-Free Report), Celgene (Nasdaq:CELG-Free Report) and First Trust
Amex Biotechnology Index Fund (AMEX:FBT-Free Report).


3 Biotech ETFs Crushing the Market

Biotechnology ETFs are among the fasting growing companies in the health care
world and are at the forefront of the sector rotation movement. As such, they
look to benefit from the broad move away from boring low growth firms, and
into higher growth, riskier sectors (read Biotechnology ETF Investing 101).

Biotech ETFs are also seeing truly impressive levels of momentum as of late,
crushing not only the overall market, but broader health care sector funds as
well. In fact, over the past six months, the average outperformance of the
biotech ETF sector over the broader health care market has been about 800
basis points, suggesting that a tilt towards biotechs certainly hasn't been a
bad idea.

Industry Factors

Beyond momentum, the sector also looks well-positioned to benefit from the
coming Obamacare changes. It managed to avoid the tax issue of the medical
device space, while biotech's many new drugs look to be gobbled up by the
larger base of insured persons across the U.S.

Mergers and acquisitions have also been a big deal for biotechnology firms,
and with a return to M&A activity, this could act as a nice catalyst for the
space as well. This is especially true given that the biotech companies
generally have decent drug pipelines, and many are small and mid caps that
make for ideal takeover targets anyway (see Two ETFs for the Muddle Through

Zacks Industry Rank

If that wasn't enough, investors should also note that the biotech-genome
Zacks Industry Rank is quite favorable as well. At time of writing, this
metric came in just outside the top third overall, while the average Zacks
Rank for the industry has moved in the right direction over the past week too.

Top Biotech ETFs to Consider

Given this favorable position of the biotech industry, investors may want to
consider some of the ETFs tracking this space for exposure. While there a
number of quality choices in the space, we have highlighted some of our
favorite top performing biotech ETFs below, any of which could make for
excellent investments in today's growth-focused market:

Market Vectors Biotech ETF (AMEX:BBH-Free Report)

This ETF tracks the Market Vectors US Listed Biotech 25 Index, a benchmark of
25 companies in the biotech sector. The fund charges a reasonable 35 basis
point fee per year, and sees decent volume on assets of about $300 million
(see Two Sector ETFs to Buy in 2013).

The ETF is heavily focused on large caps and growth stocks, as more than
two-thirds of the portfolio falls in the large cap category, while about 80%
is classified as growth. With this focus, it shouldn't be too surprising to
note that the ETF doesn't really pay anything in yield, and that it isn't an
income choice for investors.

In terms of holdings, large biotech firms take the top three spots and account
for about 36% of assets, suggesting a relatively heavy level of concentration.
Six other companies make up over 4% though, so there is a decent amount of

From a performance perspective, the ETF has been extremely solid, adding about
30% over the past six months. The fund is also up 55% from a one year look,
thoroughly crushing similar funds and the broad market in the time frame.

iShares Nasdaq Biotechnology ETF (Nasdaq:IBB-Free Report)

This fund follows the NASDAQ Biotechnology Index, a benchmark of about 120
companies involved in biomedical research. The ETF charges 48 basis points a
year in fees, and sees great volume on assets of just over $3 billion.

Growth stocks are once again a big part of this fund accounting for about 80%
of the total. However, large caps aren't as dominant here, accounting for just
over 50% of assets in IBB, leaving plenty for pint sized firms.

This fund's holdings profile is similar to BBH, as GILD, AMGN, and BIIB all
find their way into the top five. However, the top holding here is Regeneron
(Nasdaq:REGN-Free Report), while Celgene (Nasdaq:CELG-Free Report) also finds
its way into the fourth position at roughly 6.7% of assets (see Forget Big
Pharma It Is Time for a Biotech ETF).

In terms of performance, this ETF has also been a solid performer, adding a
whopping 30% over the past six months. The ETF has also done quite well in the
trailing one year time frame, gaining an impressive 44.9% in that period.

First Trust Amex Biotechnology Index Fund (AMEX:FBT-Free Report)

For an equal weight approach to investing in biotechnology, investors have FBT
a fund that tracks the Amex Biotechnology Index. Investors have to pay a bit
more for this equal weight exposure though, as costs come in at 60 basis
points a year, though volume and assets are still solid.

This approach also results in a bit of a value tilt, though growth stocks
still make up a majority of assets in this ETF. Additionally, large caps make
up just 40% of the fund, so there is definitely a tilt towards small companies
that could be excellent takeover targets.

Beyond noting that each stock makes up roughly the same proportion in this
ETF, investors should also note that just 20 stocks are in FBT's basket. So,
on average, each company will only make up about 5% of the total, though this
can fluctuate in between rebalancing dates.

This has been the worst of the three in terms of performance, but it has still
beaten out broad benchmarks, adding about 27.5% in the past six months. Longer
term the performance has also been shakier, adding 'just' 37%, though its
focus on smaller securities could help it outperform if an M&A wave hits the
biotech world (see Food ETFs in Focus on Deal Wave).

Bottom Line

Biotechnology ETFs have had a pretty solid run over the past few months,
outpacing broad markets, and the health care sector in general as well. Given
the current trend in the market towards high growth sectors and away from
dividends, these firms could certainly continue their recent run and move
higher in the summer months.

This could be especially true given the decent industry rank for this segment,
how well the sector is positioned for Obamacare implementation, and the many
M&A opportunities in this corner of the investing world. So, if you are
looking for high growth, high momentum play, any of the aforementioned biotech
ETFs could definitely be a solid pick for the weeks and months ahead.

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Click here for your free subscription to Profit from
the Pros.

Get the full Report on BBH - FREE

Get the full Report on IBB - FREE

Get the full Report on REGN - FREE

Get the full Report on CELG - FREE

Get the full Report on FBT - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers
displayed in this press release.

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.